Sin Azucar s.r.o.

The medical center is at the forefront of cardiovascular research, focusing on innovative treatments for atherosclerotic cardiovascular disease and elevated lipoprotein(a) levels. The center's research aims to reduce the risk of major adverse cardiovascular events (MACE-4), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization.

• Atherosclerotic Cardiovascular Disease
• Elevated Lipoprotein(a)
• Major Adverse Cardiovascular Events (MACE-4)

Through cutting-edge clinical trials, the center is pioneering new therapies that could significantly improve patient outcomes in cardiovascular health.

Specializing in the intersection of metabolic disorders and renal health, the center conducts research on the effects of innovative treatments for obesity-related complications. The focus is on reducing serious heart-related complications and preventing the worsening of kidney function in individuals with obesity.

• Obesity and Overweight
• Cardiovascular Outcomes
• Kidney Function

The center's research contributes to the development of therapies that address both cardiovascular and renal outcomes, offering hope for improved quality of life for patients.

Focusing on type 2 diabetes mellitus and its associated cardiovascular risks, the center is engaged in research comparing the efficacy of novel treatments. The goal is to assess the impact of these treatments on major cardiovascular events (MACE-3), including death from cardiovascular causes, myocardial infarction, and stroke.

• Type 2 Diabetes Mellitus
• Cardiovascular Risk
• Major Adverse Cardiovascular Events (MACE-3)

By exploring new therapeutic options, the center aims to enhance the standard of care for patients with type 2 diabetes and high cardiovascular risk.